To assess whether the response to the selected inhibitors was specifically associated to the mutational status of B-ALL primary cells, we compared it with B-ALL cases that proved negative for FLT3, KRAS and NRAS mutations. Here, FLT3 is linked to acute lymphoblastic leukemia.